PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical Development
Prostate cancer (PC) treatment has reached a milestone with the introduction of poly(ADP-ribose) polymerase (PARP) inhibitors. PARP inhibitors (PARPi) induce breaks in single-stranded and/or double-stranded DNA, resulting in synthetic lethality in cancer cells lacking functional homologous recombi...
Main Author: | Whi-An Kwon |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society for Sexual Medicine and Andrology
2024-04-01
|
Series: | The World Journal of Men's Health |
Subjects: |
Similar Items
-
PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview
by: Islam Kourampi, et al.
Published: (2023-01-01) -
Successes and challenges of PARP inhibitors in cancer therapy
by: Tiffany K Ricks, et al.
Published: (2015-10-01) -
Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
by: Ashwin Ragupathi, et al.
Published: (2023-03-01) -
PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
by: Anthony Gonçalves, et al.
Published: (2020-05-01) -
Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
by: Chuanlin Wang, et al.
Published: (2022-12-01)